Assoc Editor-In-Chief @WikiDoc | PGY-2 @onebklynhealth | Former GI-Onco research Asst @MaimoHealth | GI cancers | @IMRC_Team | Bongos |
Brooklyn, NY
Joined March 2024
- Tweets361
- Following689
- Followers299
- Likes1.1K
Rithish retweeted
6 years ago, I had the chance to publish a paper that would end up changing my academic life
It was a review article exploring the surprising activity of certain ADCs in “HER2-low” breast cancer, a newly emerging entity whose relevance was still uncertain.
We tried to connect the dots, asking if HER2-low was a subtype vs just a target, wondering whether this concept could one day translate into meaningful benefits for patients.
6 years later, that article has reached 1,000 citations. My career has gifted me more than I could ever have imagined. More importantly, what was once an intriguing scientific observation has become a clinical reality: countless patients with HER2-low breast cancer now live longer thanks to T-DXd.
A reminder of how far science can take us in just a few years.
Grateful to everyone who has been part of this journey!
ascopubs.org/doi/10.1200/JCO…
Glad to announce that our new paper has been published 😀
“Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma”
Grateful to all my co-authors for their contributions and collaboration in bringing this work to publication.
#HemeOncology #MultipleMyeloma
Honored to have presented my work at the Lymphoma, Leukemia & Myeloma Congress! Grateful for the opportunity to share our research, learn from experts in the field @llmcongress
#LLM2026 #Hematology #Oncology
Rithish retweeted
⭐️Really loving the wording in the daraxonrasib FDA approval. Clear autonomy for physicians, centered on patient needs.
👉🏼“The approval is for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy”
👉🏼This is how oncology should move forward @OncoAlert @matthewherper @oncodaily @OpenEvidence @FDA @FDAOncology @FDAMedia @DrSamuelBHume
🚨🚨🚨⭐️HUGE news & a MAJOR milestone in oncology‼️
👉🏼The FDA just approved the first targeted therapy for metastatic pancreatic cancer a breakthrough in precision oncology and a landmark step in making the BIG KRAS officially druggable ( beyond KRAS K12C) ❗️
$RVMD
👉🏼A new era in the fields battle against a devastating Emperor of all maladies. #precisionmedicine #KRAS
@OncoAlert @oncodaily @DavidHongMD @Aiims1742 @DrShubhamPant @GIcancerDoc @EileenMOReilly
fda.gov/news-events/press-an…
Rithish retweeted
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer - The New York Times nytimes.com/2026/08/26/scien…
Rithish retweeted
🚨 FDA APPROVAL | First-in-class RAS inhibitor in metastatic pancreatic cancer
The FDA has approved Rasonque (daraxonrasib), an oral once-daily RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received ≥1 prior systemic therapy or are not candidates for multiagent systemic therapy.
📊 Randomized trial | N=500
• Median OS: 13.2 months
• Standard chemotherapy: 6.7 months
➡️ Nearly doubling median overall survival in previously treated metastatic disease.
⚠️ Common adverse events included rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite and hemorrhage.
💡 Why it matters:
RAS has long been one of the hardest oncogenic drivers to target. This approval introduces a new targeted treatment strategy into one of oncology’s highest-unmet-need diseases.
Verdict: 🔥 Practice Changing
@FDAOncology @OncoAlert
#PancreaticCancer #Oncology #RAS #FDA
Rithish retweeted
🚨🚨🔔🔔We have not one but two blood 🩸 tests FDA approved for CRC screening in average risk individuals in the US
👉🏼Implementation requires special attention, with focus on the unscreened 🧐
@NYULH_GastroHep @AmCollegeGastro
🩸 #SimpleScreenCRC @Freenome is the second FDA-approved blood-based biomarker test for #ColorectalCancer.
🗨️”A blood-based test provides another way to reach unscreened patients,” said @AasmaShaukatMD.
vist.ly/5diqg
Link - mdpi.com/2077-0383/15/6/2337
Rithish retweeted
😅
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊
🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications
💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban
nejm.org/doi/full/10.1056/NE…
Rithish retweeted
Saindo do forno! 🔥
Apixabana ou rivaroxabana para tratar TEV agudo? Ambos são DOACs amplamente utilizados, mas nunca haviam sido comparados em um RCT.
O estudo COBRRA (NEJM 2026) tentou responder uma pergunta clinicamente relevante:
➡️ Qual deles causa menos sangramento?
Such a welcoming and timely update to share during #CRCAwarenessMonth!
Let’s continue raising awareness for colorectal cancer prevention and early detection. 💙
#Colorectalcarcinoma
Rithish retweeted
ImmunoXXL Phase II Study: Liver Transplantation After Atezolizumab–Bevacizumab Downstaging in Advanced HCC
In a prospective study, 16 patients with intermediate and advanced HCC beyond extended transplant criteria were downstaged with Atezo–Bev and underwent liver transplantation.
Key outcomes
• 2-year RFS: 90%
• 2-year OS: 94%
• Acute rejection: 25%
The authors conclude that liver transplantation should be considered after HCC response to immunotherapy.
@DJPinato @MariannaMaspero @MarcoBongini
oncodaily.com/oncolibrary/im…
#HCC #LiverCancer #Immunotherapy #TransplantOncology #Oncology
Another cancer presentation on the way
This time in my niche of colorectal cancer. Looking forward to learning, sharing insights, and connecting with peers from similar backgrounds.
📍 Chicago - May
#Colorectal @ASCO
New Study of ours is out now🚨.!
Key Insight from Our Recent Meta-Analysis: CRC in Solid Organ Transplant Recipients
Please do study and let us know what you think of.! Thank for the amazing team and work display
#oncology #CRC
Link - onlinelibrary.wiley.com/doi/…
